FDA vs EMA vs MHRA vs Health Canada β who's most active?
This comparison suggests that EMA is currently the most active environment by document volume, with MHRA also relatively busy and Health Canada moderately active, while FDA output appears lower in this snapshot; that may indicate faster-moving expectations in Europe and the UK than in the US over this period. Sponsors should consider that multi-market filing strategies may need the greatest regulatory bandwidth for EU/UK alignment, with more frequent horizon scanning, tighter change-control, and earlier dossier harmonization to absorb divergent guidance. The lower FDA count could suggest less noise rather than less complexity, so companies should avoid overweighting one region and instead plan flexible regulatory resources that can respond to uneven activity across jurisdictions.
Get personalised regulatory alerts delivered to your inbox or Telegram β filtered to your therapeutic areas, agencies, and document types.
Start Free 14-Day Trial